1 — α Equivariant Confidence Rules for Convex Alternatives are α/2–Level Tests—With Applications to the Multivariate Assessment of Bioequivalence

Journal of the American Statistical Association

Volumn 94, Issue 448, 1999, Pages 1311-1319

  Munk, Axel ^a   Pflüger, Rafael ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Confidence inclusion rules; Convex hypotheses; Equivalence; Equivariance; Hotelling's T2 test; Multivariate bioequivalence

Indexed keywords

EID: 0442309496     PISSN: 01621459     EISSN: 1537274X     Source Type: Journal    
DOI: 10.1080/01621459.1999.10473883     Document Type: Article

References (35)

1. Aitchinson, J. (1964), "Confidence-Region Tests," Journal of the Royal Statistical Society, Ser. B, 26, 462-476.
2. Anderson, T. W. (1984), An Introduction to Multivariate Statistical Analysis (2nd ed.). New York: Wiley.
3. Bauer, P., and Kieser, M. (1996), "A Unifying Approach for Confidence Intervals and Testing of Equivalence and Differences," Biometrika, Vol. 83, 934-937.
4. Berger, R. L. (1982), "Multiparamcter Hypothesis Testing and Acceptance Sampling," Technometrics, 24, 295-300.
5. Berger, R. L., and Hsu, J. C. (1996), "Biocquivalence Trials, Intersection-Union Tests, and Equivalence Confidence Sets" (with discussion). Statistical Science, 11, 283-319.
6. Brown, L. D., Casella, G., and Hwang, J. T. G. (1995), "Optimal Confidence Sets, Bioequivalence, and the Limaçon of Pascal." Journal of the American Statistical Association, 90, 880-889.
7. Brown, L. D., Hwang, J. T. G., and Munk, A. (1998), "An Unbiased Test for the Bioequivalence Problem," The Annals of Statistics, 25, 2345-2367.
8. Chinchilli, V. M., and Elswick, R. K., Jr. (1997), "The Multivariate As-sessment of Bioequivalence," Journal of Biopharmaceutical Statistics, 7, 113-123.
9. Chow, S.-C., and Liu, J.-P. (1992), Design and Analysis of Bioavailability and Bioequivalence Studies, New York: Marcel Dekker.
10. EC-GCP (1993), "Biostatistical Methology in Clinical Trials in Applications for Marketing Authorization for Medical Products," CPMP Working Party on Efficacy of Medical Products, Commision of the European Communities, Brussels, Draft Guideline edition.
11. Endrenyi, L., Fritsch, S., and Yan, W. (1991), "Cmax/AUC is a Clearer Measure Than Cmax for Absorbtion Rates in Investigation of Bioequivalence," International Journal of Clinical Pharmacology and Therapeutic Toxicology, 29, 394-399.
12. Greenwald, A. G. (1975) "Consequences of Prejudice Against the Null Hypothesis," Psychological Bulletin, 82, 1-20.
13. Hauck, W. W., and Anderson, S. (1996), Comment on "Bioequivalence Trials, Intersection-Union Tests and Equivalence Confidence Sets." Statistical Science. 11, 303.
14. Hodges, J. L., and Lehmann, E. L. (1954), 'Testing the Approximate Validity of Statistical Hypotheses," Journal of the Royal Statistical Society, Ser. B, 16. 261-268.
15. Hsu, H. C., Lu, H. L., and Chan, K. K. H. (1995), "A Novel Multivariate Approach for Estimating the Degree of Similarity in Bioavailability Between Two Pharmaceutical Products," Journal of Biopharmaceutical Statistics, 84, 768-772.
16. Lehmann, E. L. (1986), Testing Statistical Hypotheses (2nd ed.), New York: Wiley.
17. Metzler, C. M. (1991), "Sample Sizes for Bioequivalence Studies," statistics in Medicine, 10, 961-970.
18. Munk, A. (1993), "An Improvement on Commonly Used Tests in Bio-equivalence Assessment." Biometrics, 49. 1225-1230.
19. Munk, A. (1994), "Correspondence: On a Method of Combining the Double t-Test and the Anderson-Hauck Test," Biometrics, 50, 884-886.
20. Nakashima, K., Takahashi, K., Azumi, T., and Ishida, G. (1990), "Extero-ceptive Suppression of the Masseter and Temporalis Muscules Produced by Electric Stimulation of the Mental Nerve in Patients With Parkinson's Disease," Acta Neurologica Scandinavia, 81, 407-410.
21. Rockafellar, R. T. (1970), Convex Analysis, Princeton, NJ: Princeton University Press.
22. Rogers, J. L., Howard, K. I., and Vessey, J. T. (1993), "Using Significance Tests to Evaluate Equivalence Between Two Experimental Groups," Psychological Bulletin, 113, 553-565.
23. Schall, R. (1995), "Assessment of Individual and Population Bioequivalence Using the Probability That Bioavailabilities arc Similar," Biometrics. 51, 615-626.
24. Schall, R., Groenewald, P. C. N., Potgieter, L. A., and Luus, H. G. (1996), "Multivariate Assessment of Bioequivalence," technical report, University of the Orange Free State.
25. Schoenen, J. (1993), "Exteroceptive Suppression of Temporalis Muscle Activity: Methodological and Physiological Aspects," Cephalalgia, 13, 3-10.
26. Schoenen, J., Jamart, B., Gererd, P., Lenarduzzi, P., and Delwaide, P. J. (1987), "Exteroceptive Suppression of Temporalis Muscle Activity in Chronic Headache," Neurology, 37, 1834-1837.
27. Schuirmann, D. J. (1987), "A Comparison of the Two One-Sided Tests Procedures and the Power Approach for Assessing the Equivalence of Bioavailability,'' Journal of Pharmacokinetics and Biopharmaceutics, 15, 657-680.
28. Sheiner, L. B. (1992), "Bioequivalence Revisited," Statistics in Medicine, 11. 1777-1788.
29. Steinijans, V., Sauter, R., Hauschke, D., and Elze, M. (1995), "Metrics to Characterize Concentration-Time Profiles in Single-and Multiple-Dosc Bioequivalence Studies," Drug Information Journal, 29, 981-987.
30. Steinhoff, B. J., Fangmeier, B., Reimers, C. D., and Paulus, W. (1996), "Einflußvon Epilepsien und Antiseptischer Medikation auf die Exterozeptive Suppression der Temporalismuskelaktivität," Zeitschrift für Elektroenzephalographie. Elektromyographie und verwandte Gebiete, 2, 65-69.
31. Tsong, Y., Hammerstrom, T., Sathe, P., and Shah, V. P. (1996), "Statistical Assessment of Mean Differences Between Two Dissolution Data Sets," Drug Information Journal, 30, 1105-1112.
32. U.S. Food and Drug Administration (1992), "Bioavailability and Bioequiv-alence Requirements," U.S. Government Printing Office, U.S. Code of Federal Regulations, Vol. 21, Washington, DC: U.S. Government Printing Office, Chap. 320.
33. Victor, N. (1987), "Relevant Differences and Shifted Null Hypotheses," Methods of Information in Medicine, 26, 109-116.
34. Westlake, W. J. (1988), "Bioavailability and Bioequivalence of Pharmaceutical Formulations," in Biopharmaceutical Statistics for Drug Development, ed. K. E. Peace, New York: Marcel Dekker, 329-352.
35. Wang, W., DasGupta, A., and Hwang, J. T. G. (1997), "Statistical Tests for Multivariate Bioequivalence," technical report, Cornell University.